CHARM study backs triple-drug therapy for CHF: undercuts existing guidelines. (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity, congestive heart failure).(Cardiovascular Medicine)

Publication: Internal Medicine News

Publication Date: 15-OCT-03

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2003 International Medical News Group

VIENNA -- Data from a major clinical trial are prompting a reversal of opinion about the appropriateness of adding an angiotensin receptor blocker to the treatment of patients with congestive heart failure who are already on an ACE inhibitor and a [beta]-blocker.

The findings challenge existing practice guidelines--and illustrate the hazards of basing medical practice upon the results of post hoc subgroup analysis of trial data.

For the past 3 years, practice guidelines have strongly urged physicians to avoid this three-drug combination in patients with congestive heart failure (CHF). This recommendation was based upon the best available data at the time, a retrospective subgroup analysis from the randomized Valsartan Heart...

Read the full article for free courtesy of your local library.